Answers are grounded in this paper and cite their sources.
Our data provide a detailed picture of RNA editing landscape in normal brain and GBM, exploring A-to-I RNA editing regulation, disclosing unexpected editing implications for GBM patient stratification and identification of gender-dependent high-risk patients, and suggesting COG3 I/V as an eligible site for future personalized targeted gene therapy.
No takes yet. Share an insight, caveat, or question.
Silvestris et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: